Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens

Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that an analysis of Baxdela™ (delafloxacin) activity against fluoroquinolone-susceptible and fluoroquinolone-resistant Staphylococcus aureus isolates from individuals who had participated in PROCEED, the company’s Phase 3 clinical trials, was published in the journal Antimicrobial Agents and Chemotherapy.